electroCore Posts 43% Revenue Surge on VA, Quell Growth
Event summary
- Q1 2026 revenue hit $9.6M, up 43% YoY, driven by VA prescription sales and Quell adoption
- Adjusted EBITDA loss improved 24% YoY to $2.3M despite $1.9M in one-time leadership transition costs
- Truvaga international expansion began with UK launch in January 2026
- Michael Fox joined as COO in April 2026 with 35 years of healthcare commercial experience
- Reaffirmed 30% annual revenue growth guidance for full-year 2026
The big picture
electroCore's strong Q1 performance highlights the strategic value of its VA channel and recent Quell acquisition, positioning it as a niche player in bioelectronic medical devices. The company's ability to improve marketing efficiency in its consumer wellness segment while expanding internationally suggests a balanced growth strategy. However, sustaining profitability improvements will depend on managing operating leverage as it scales commercial operations.
What we're watching
- Commercial Execution
- Whether Michael Fox can scale the commercial organization efficiently to translate revenue growth into bottom-line improvement
- Product Pipeline
- The pace at which Quell Relief for lower extremity pain launches in H2 2026 and its potential market impact
- Regulatory Progress
- How ongoing PTSD clinical studies with Acacia Clinics and Vagus Nerve Society could expand gammaCore's therapeutic indications
Related topics